Show notes
In this episode of Medsider Radio, we had an insightful chat with Amarpreet Sawhney, inventor, serial entrepreneur, and CEO of a few startups, including Instylla, which is developing polymerizing liquid embolics that can be used to shut down blood supply to hypervascular tumors and control bleeding.Amar is also the CEO of Rejoni, Sealonix, and Pramand. His FDA-approved inventions include ReSure Sealant and Dextenza for ophthalmology, DuraSeal for neurosurgery, FocalSeal for lung surgery, Mynx for femoral puncture sealing, and SpaceOAR for prostate cancer radiotherapy. Together, they have impacted over 8 million patients globally.In this episode, Amar shares his frameworks on risk assessment for medtech startups, tips on clinical study design, and how to prioritize indications when working on platform technologies.Before we dive into the discussion, I wanted to mention a few things:First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a Medsider premium membership. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!We recently introduced some fantastic additions exclusively for Medsider premium members, including playbooks, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and a curated investor database to help you discover your next medical device or health technology investor!In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of Medsider Mentors at no additional cost, including the latest Medsider Mentors Volume VI. If you’re interested, go to medsider.com/subscribe to learn more.Lastly, if you'd rather read than listen, here's a link to the full interview with Amar Sawhney.